The use of biologics in psoriasis and psoriatic arthritis management is not linked to the risk of cardiovascular or venous thromboembolic events.

Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...

Nevertheless, 68% of the $3.5 billion global psoriasis market is captured by biologic therapies; topical agents and conventional systemic drugs account for ∼25% and ∼7%, respectively.

Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching among patients with psoriasis ...

For moderate to severe cases, systemic biologics work to ... together into the newer novel agents class that are indicated for all levels of severity in psoriasis. Unlike traditional topical ...

SB5, an adalimumab biosimilar approved in the US, is showing to be safe and effective for patients with psoriasis in the long ...

Though much is still unknown about psoriasis, experts believe it could ... Treatments include phototherapy, steroids, topicals, and newer biologic agents which suppress the immune response.

A new study finds no significant differences in cardiovascular and thromboembolic risks among biologics for psoriasis or ...

A study found patients treated with interleukin inhibitors did not experience a difference in the rates of major adverse ...

Immunosuppressive agents prevent an effective immune ... but they still recommend vaccination. People with psoriasis should continue their current biologic or immunosuppressive therapy when ...

These findings may offer more personalized treatment and prevention recommendations for patients with psoriasis.